Opexa offering cuts stock in half to fund MS immunotherapy
This article was originally published in Scrip
Opexa Therapeutics priced 12 million shares after the market closed on 7 August at $1.50 per share – nearly half of the company's $2.92 closing price – to raise $18 million for its ongoing Phase IIb clinical trial for the personalized multiple sclerosis immunotherapy Tcelna.
You may also be interested in...
Poseida, Nkarta and Inventiva raised $224m, $252m and $107.7m, respectively. Also, Forbion raised €185m ($208m) of a new €250m fund and Blackstone closed the last $1.2bn of its $4.6bn fund for public and private company deals, and Ascendis led recent follow-ons with a $569.2m offering.
Some analysts see a 50-50 chance of US FDA approval despite the controversial dataset for the anti-amyloid antibody, but at least one expects an eventual CRL requesting a third Phase III trial.
A Phase I study for allogeneic therapy UCARTCS1A was put on clinical hold after a patient died. High dosing and double exposure to cyclophosphamide pre-conditioning may have played a role.